Lymphocytes, Tumor-Infiltrating
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges
FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma
Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating